At SABCS this year, we will share new data from our robust portfolio and advanced therapeutic platforms in breast and women’s cancer, showcasing our bold science in research.
Novartis continues to pursue scientific breakthroughs with the ambition to transform lives and renew patients’ hopes for the future. Novartis products reach more than 800 million people globally and we are finding innovative ways to expand access to our medicines.
Novartis is uniquely positioned to lead the next wave of novel investigational treatments through our strengths in 4 therapeutic platforms: targeted therapy, radioligand therapy, cell & gene therapy, and immunotherapy.
